[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353821-105":59,"doc-detail-353821-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncological-genetic-counseling-in-hereditary-breast-and-ovarian-cancers-and-lynch-syndrome-high-risk-subjects-evaluation-of-efficacy-and-outcomes-using-the-genomics-outcome-scale","Oncological Genetic Counseling in Hereditary Breast and Ovarian Cancers and Lynch Syndrome High-Risk Subjects - Evaluation of Efficacy and Outcomes Using the Genomics Outcome Scale","","Validated instruments to assess the quality of oncological genetic counseling (OGC) remain limited. The study evaluates OGC effectiveness using an Italian-translated Genomics Outcome Scale (GOS) questionnaire. Clinical variables were analyzed for associations with GOS responses using Fisher’s exact test or Chi-square tests at p=0.05. Among 209 respondents, high affirmative understanding of counseling content, relatives’ risk, concern, surveillance, decisional ability, and future planning was reported, with differences linked to age and education, and test result for certain domains. Overall, GOS indicates OGC usefulness and effectiveness.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncological-genetic-counseling-in-hereditary-breast-and-ovarian-cancers-and-lynch-syndrome-high-risk-subjects-evaluation-of-efficacy-and-outcomes-using-the-genomics-outcome-scale/353821/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncological-genetic-counseling-in-hereditary-breast-and-ovarian-cancers-and-lynch-syndrome-high-risk-subjects-evaluation-of-efficacy-and-outcomes-using-the-genomics-outcome-scale/353821.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What gap does the study address about oncological genetic counseling (OGC)?","Question",{"text":112,"@type":113},"Validated tools to assess the quality of OGC are lacking. The research targets this gap by evaluating effectiveness with a structured questionnaire.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was OGC effectiveness measured in this study?",{"text":117,"@type":113},"Effectiveness was assessed using the Italian-translated Genomics Outcome Scale (GOS) questionnaire, analyzing how clinical variables relate to different GOS responses.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding patients’ understanding and empowerment?",{"text":121,"@type":113},"Most participants reported affirmative understanding across key domains, including counseling content, relatives’ risk, concern, surveillance, decision-making ability, and future planning. Higher empowerment appeared in younger patients and those with higher education.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353821,1790196645,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Human Mutation  \nRESEARCH ARTICLE  OPEN ACCESS   \nOncological Genetic Counseling in Hereditary Breast and Ovarian Cancers and Lynch Syndrome High-Risk Subjects:  \nEvaluation of Efficacy and Outcomes Using the Genomics Outcome Scale  \nElena Maccaroni1 | Rebecca Chiariotti2 | Riccardo Giampieri3 | Francesca Bianchi3 | Cristiana Brugiati2 | Laura Belvederesi2 | Elisa Ambrosini2 | Natalia Chiodi2 | Emma Nicol Serritelli2 | Francesca Morgese1 | Veronica Agostinelli1 | Giulia Mentrasti1 | Cecilia Copparoni2 | Alice Magnarini2 | Chiara De Filippis2 | Elena Burattini2 | Raffaella Bracci4 | Rita Chiari4 | Michela Del Prete5 | Renato Bisonni5 | Luca Faloppi6 | Nicola Battelli7 | Rosa Rita Silva8 | Rossana Berardi3  \n1Department of Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy | 2Department of Oncology, Università Politecnica delle Marche, Ancona, Italy | 3Department of Oncology, Università Politecnica delle Marche, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy | 4Medical Oncology Unit, AST1, Pesaro, Italy | 5Medical Oncology Unit, Ospedale A. Murri, Fermo, Italy | 6Medical Oncology Unit, Ospedali Santa Maria  \nDella Pietà e Bartolomeo Eustachio-AST di Macerata, Camerino, San Severino Marche, Italy | 7Medical Oncology Unit, Macerata Hospital, Macerata, Italy | 8Medical Oncology Unit, AST2, Fabriano, Italy  \nCorrespondence: Elena Maccaroni (elena.maccaroni@ospedaliriuniti.marche.it)  \nReceived: 28 July 2025 | Revised: 6 December 2025 | Accepted: 7 January 2026  \nAcademic Editor: Stuart Scott  \nKeywords: genetic test | Genomics Outcome scale | hereditary breast and ovarian cancers | hereditary cancers | Lynch syndrome | oncological genetic counseling  \nABSTRACT  \nBackground: Validated tools assessing oncological genetic counseling (OGC) quality are lacking.  \nMethods: We assessed OCG effectiveness using italian-translated version of the Genomics Outcome Scale (GOS) questionnaire. Clinical variables were collected and their association with different answers was assessed by Fisher's exact test or Chi-square test for either dichotomous or other categorical variables, respectively, with level of statistical significance p = 0.05.  \nResults: Between November 2024 and February 2025, 209 subjects who received the complete OGC program at Our Center responded to the questionnaire; median age was 56 years (25–81). Most (76%) had breast cancer, 72% received a negative test, 15% positive test, and 13% noninformative test with variant of unknown significance (VUS) . Most patients answered affirmatively to Question 1, focused on OGC understanding: age (p = 0.0181) and education (p = 0.0028) yielded different answers. Question 2, assessing relatives risk understanding, was answered completely/partially affirmative by 94% of subjects: test result (negative noninformative vs. positive vs. VUS) was associated (p = 0.0175) with different answers. To Question 3, related to concern, 65% confirmed their worry: education (p = 0.0392) and cancer type (p = 0.0128) yielded different answers. In Question 4, focused on surveillance understanding, 77% declared full or partial awareness, regardless of examined factors. In Question 5, enquiring decisional ability for themselves or family members, 72% stated they were completely/partially able to make decisions. Education (p = 0.0287) and genetic test result (p = 0.0090) yielded different answers. In Question 6, reflecting future planning, 69% responded completely/almost completely affirmatively, 17% were uncertain, and 14% responded partially/completely negatively, regardless of examined clinical factors.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nCopyright © 2026 Elena Maccaroni et al. Human Mutation published by John Wiley & Sons Ltd.  \nHuman Mutation, 2026; 2026:7754087 1 of 14  \n[https://doi.org/10.1155/humu/77540","cbCaivuApeqyx3Kg","https://ap.wps.com/l/cbCaivuApeqyx3Kg","pdf",877615,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What gap does the study address about oncological genetic counseling (OGC)?\",\"answer\":\"Validated tools to assess the quality of OGC are lacking. The research targets this gap by evaluating effectiveness with a structured questionnaire.\"},{\"question\":\"How was OGC effectiveness measured in this study?\",\"answer\":\"Effectiveness was assessed using the Italian-translated Genomics Outcome Scale (GOS) questionnaire, analyzing how clinical variables relate to different GOS responses.\"},{\"question\":\"What were the main findings regarding patients’ understanding and empowerment?\",\"answer\":\"Most participants reported affirmative understanding across key domains, including counseling content, relatives’ risk, concern, surveillance, decision-making ability, and future planning. Higher empowerment appeared in younger patients and those with higher education.\"}]","Oncological Genetic Counseling in Hereditary Breast and Ovarian Cancers and Lynch Syndrome High-Risk Subjects - Evaluation of Efficacy and Outcomes Using the Genomics Outcome Scale | PDF",1790107407,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75775bd59b21956395e97759dc54e71d.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/022b3d9818dd0e110c23f4f95044d371.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/223aed56c4204c32ef69b6f179a27a33.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e76e0e08b87c485534a2592b0f80654.webp",980,1287]